# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Seri...
B. Riley Securities analyst Mayank Mamtani reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $55 price target.
- Balance sheet strengthened with long-term, non-dilutive capital- $400 million funded at close with the potential to draw an a...
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price ta...